Perennial Allergic Rhinitis Drug Market is Anticipated to Increase at a Stable CAGR over the Forecast Period (2023 to 2029)
The global perennial allergic rhinitis drug market is anticipated to grow at a significant CAGR of 4.0% during the forecast period 2023-2029. The increased awareness of allergic responses around the globe is likely to fuel the growth of the perennial allergic rhinitis market. Additionally, the high quality of drugs and nasal sprays supplied by manufacturers for the treatment of chronic allergic rhinitis is predicted to fuel the growth of the market.
For instance, in October 2021,
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. signed a agreement with
Marinomed Biotech AG, whereby the company would gain the rights for the
development, manufacture, and commercialization of Budesolv in China which is
an indicated for allergic rhinitis. The signing of the license agreement will
further expand the company’s product line and enhance Luoxin's competitive edge
in the area of respiratory diseases. Further, in September 2021, Hikma
Pharmaceuticals PLC announced the signing of an exclusive US license agreement
with FAES Farma S.A. to commercialise Bilastine tablets, a non-sedating
second-generation antihistamine molecule for the treatment of allergic rhinitis
and urticaria.
To Request a Sample of our Report on Perennial Allergic
Rhinitis Drug Market: https://www.omrglobal.com/request-sample/perennial-allergic-rhinitis-drug-market
Market Coverage
·
The market number available for – 2022-2029
·
Base year- 2022
·
Forecast period- 2023-2029
Segment Covered-
·
By Type
·
By Application
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
·
Competitive Landscape - including, GlaxoSmithKline
PLC, Sanofi SA, Merck & Co. inc., Pfizer Inc., Novartis International AG,
among others.
Perennial Allergic Rhinitis Drug Market Report Segment
By Type
·
Antihistamines
·
Asapiprant
·
APC-3000
·
Bilastine
·
Others
By Application
·
Hospitals
·
Clinics
·
Others
A
full Report of Perennial Allergic
Rhinitis Drug Market is Available @ https://www.omrglobal.com/industry-reports/perennial-allergic-rhinitis-drug-market
Perennial Allergic Rhinitis Drug Market Report
Segment by Region
North America
· United
States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest
of Europe
Asia-Pacific
· India
· China
· Japan
· South
Korea
· Rest
of APAC
Rest of the World
•
Latin America
•
Middle East and Africa
Company
Profiles
• AstraZeneca
PLC
• Boehringer-Ingelhiem
International GmbH
• Faes
Farma SA
• GlaxoSmithKline
PLC
• Glenmark
Pharmaceuticals Ltd.
• Hisamitsu
Pharmaceuticals Co. Inc.
• Johnson
& Johnson Services Ltd.
• Merck
& Co. Inc.
• Novartis
International AG
• Pfizer
Inc.
• Sanofi
SA
• Shandong
Luoxin Pharmaceutical Group Stock co., ltd.
• Teva
Pharmaceutical Industries Ltd.
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
For More Customized Data,
Request for Report Customization @ https://www.omrglobal.com/report-customization/perennial-allergic-rhinitis-drug-market
About Orion Market Research
Orion Market Research (OMR) is a
market research and consulting company known for its crisp and concise reports.
The company is equipped with an experienced team of analysts and consultants.
OMR offers quality syndicated research reports, customized research reports,
consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services
through another subsidiary Encanto
Technologies.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment